Skip to main content
Erschienen in: Drugs & Aging 3/2008

01.03.2008 | Review Article

Clinical Efficacy of Esomeprazole in the Prevention and Healing of Gastrointestinal Toxicity Associated with NSAIDs in Elderly Patients

verfasst von: Dr Corrado Blandizzi, Marco Tuccori, Rocchina Colucci, Giovanni Gori, Matteo Fornai, Luca Antonioli, Narcisa Ghisu, Mario Del Tacca

Erschienen in: Drugs & Aging | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

NSAIDs are widely prescribed for the treatment of pain, inflammation and rheumatic disorders, but their use is associated with adverse gastrointestinal effects, ranging from dyspeptic symptoms and peptic ulcers to more serious complications. Elderly patients are at high risk of experiencing NSAID-induced gastrointestinal tract injury and should be considered candidates for prophylactic pharmacological therapy. In studies conducted in adult patients, proton pump inhibitors (PPIs) such as esomeprazole have been shown to prevent or reduce NSAID-induced gastrointestinal injury. The beneficial effects of esomeprazole can be ascribed largely to its ability to maintain sustained inhibition of gastric acid secretion, although there is evidence to suggest that pharmacodynamic properties unrelated to acid inhibition may also contribute to the gastroprotective effects of this agent. Although there are limited data on the use of esomeprazole specifically in elderly patient populations, studies of patients at high risk of NSAID-induced gastrointestinal toxicity because of advanced age indicate that this PPI is both effective and well tolerated when administered in conjunction with NSAIDs. Thus, esomeprazole can be regarded as a useful option for prophylactic therapy in elderly patients receiving long-term NSAID therapy.
Literatur
1.
Zurück zum Zitat Dubois RW, Melmed GY, Henning JM, et al. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther 2004; 19(2): 197–208PubMedCrossRef Dubois RW, Melmed GY, Henning JM, et al. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther 2004; 19(2): 197–208PubMedCrossRef
2.
Zurück zum Zitat Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002; 287(3): 337–44PubMedCrossRef Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002; 287(3): 337–44PubMedCrossRef
3.
Zurück zum Zitat Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340(24): 1888–99PubMedCrossRef Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340(24): 1888–99PubMedCrossRef
4.
Zurück zum Zitat Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002; 123(4): 1006–12PubMedCrossRef Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002; 123(4): 1006–12PubMedCrossRef
5.
Zurück zum Zitat Lanas A, Ferrandez A. Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly. Drugs Aging 2007; 24(2): 121–31PubMedCrossRef Lanas A, Ferrandez A. Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly. Drugs Aging 2007; 24(2): 121–31PubMedCrossRef
6.
Zurück zum Zitat Singh G, Triadafilopoulos G. Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. Int J Clin Pract 2005; 59(10): 1210–7PubMedCrossRef Singh G, Triadafilopoulos G. Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. Int J Clin Pract 2005; 59(10): 1210–7PubMedCrossRef
7.
Zurück zum Zitat Laporte JR, Ibanez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf 2004; 27(6): 411–20PubMedCrossRef Laporte JR, Ibanez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf 2004; 27(6): 411–20PubMedCrossRef
8.
Zurück zum Zitat Stillman MJ, Stillman MT. Choosing non-selective NSAIDs and selective COX-2 inhibitors in the elderly: a clinical use pathway. Geriatrics 2007; 62(2): 26–34PubMed Stillman MJ, Stillman MT. Choosing non-selective NSAIDs and selective COX-2 inhibitors in the elderly: a clinical use pathway. Geriatrics 2007; 62(2): 26–34PubMed
9.
Zurück zum Zitat Hawkey CJ, Langman MJ. Non-steroidal anti-inflammatory drugs: overall risks and management: complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 2003; 52(4): 600–8PubMedCrossRef Hawkey CJ, Langman MJ. Non-steroidal anti-inflammatory drugs: overall risks and management: complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 2003; 52(4): 600–8PubMedCrossRef
10.
Zurück zum Zitat Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109(17): 2068–73PubMedCrossRef Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109(17): 2068–73PubMedCrossRef
11.
Zurück zum Zitat Sun SX, Lee KY, Bertram CT, et al. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing utilization. Curr Med Res Opin 2007; 23(8): 1859–66PubMedCrossRef Sun SX, Lee KY, Bertram CT, et al. Withdrawal of COX-2 selective inhibitors rofecoxib and valdecoxib: impact on NSAID and gastroprotective drug prescribing utilization. Curr Med Res Opin 2007; 23(8): 1859–66PubMedCrossRef
12.
Zurück zum Zitat Laine L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs: nice or necessary? Rev Gastroenterol Disord 2004; 4Suppl. 4: S33–41PubMed Laine L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs: nice or necessary? Rev Gastroenterol Disord 2004; 4Suppl. 4: S33–41PubMed
13.
Zurück zum Zitat Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective, 1997 [Arthritis, Rheumatism, and Aging Medical Information System]. J Rheumatol 1998; 51 Suppl.: 8–16 Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective, 1997 [Arthritis, Rheumatism, and Aging Medical Information System]. J Rheumatol 1998; 51 Suppl.: 8–16
14.
Zurück zum Zitat Hawkey C, Talley NJ, Yeomans ND, et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 2005; 100(5): 1028–36PubMedCrossRef Hawkey C, Talley NJ, Yeomans ND, et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 2005; 100(5): 1028–36PubMedCrossRef
15.
Zurück zum Zitat Nielsen OH, Ainsworth M, Csillag C, et al. Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients?. Aliment Pharmacol Ther 2006; 23(1): 27–33PubMedCrossRef Nielsen OH, Ainsworth M, Csillag C, et al. Systematic review: coxibs, non-steroidal anti-inflammatory drugs or no cyclooxygenase inhibitors in gastroenterological high-risk patients?. Aliment Pharmacol Ther 2006; 23(1): 27–33PubMedCrossRef
16.
Zurück zum Zitat Naesdal J, Brown K. NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options. Drug Saf 2006; 29(2): 119–32PubMedCrossRef Naesdal J, Brown K. NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options. Drug Saf 2006; 29(2): 119–32PubMedCrossRef
17.
Zurück zum Zitat Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction, 2002 [summary article]: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002; 106(14): 1893–900PubMedCrossRef Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction, 2002 [summary article]: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002; 106(14): 1893–900PubMedCrossRef
18.
Zurück zum Zitat Blandizzi C, Fornai M, Colucci R, et al. Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage. World J Gastroenterol 2005; 11(26): 4052–60PubMed Blandizzi C, Fornai M, Colucci R, et al. Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage. World J Gastroenterol 2005; 11(26): 4052–60PubMed
19.
Zurück zum Zitat Suzuki H, Hibi T. Novel effects other than antisecretory action and off-label use of proton pump inhibitors. Expert Opin Pharmacother 2005; 6(1): 59–67PubMedCrossRef Suzuki H, Hibi T. Novel effects other than antisecretory action and off-label use of proton pump inhibitors. Expert Opin Pharmacother 2005; 6(1): 59–67PubMedCrossRef
20.
Zurück zum Zitat Johnson DA. Review of esomeprazole in the treatment of acid disorders. Expert Opin Pharmacother 2003; 4(2): 253–64PubMedCrossRef Johnson DA. Review of esomeprazole in the treatment of acid disorders. Expert Opin Pharmacother 2003; 4(2): 253–64PubMedCrossRef
21.
Zurück zum Zitat Scott LJ, Dunn CJ, Mallarkey G, et al. Esomeprazole: a review of its use in the management of acid-related disorders. Drugs 2002; 62(10): 1503–38PubMedCrossRef Scott LJ, Dunn CJ, Mallarkey G, et al. Esomeprazole: a review of its use in the management of acid-related disorders. Drugs 2002; 62(10): 1503–38PubMedCrossRef
22.
Zurück zum Zitat Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003; 23(4): 460–71PubMedCrossRef Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003; 23(4): 460–71PubMedCrossRef
23.
Zurück zum Zitat Tonini M, Vigneri S, Savarino V, et al. Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor. Dig Liver Dis 2001; 33(7): 600–6PubMedCrossRef Tonini M, Vigneri S, Savarino V, et al. Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor. Dig Liver Dis 2001; 33(7): 600–6PubMedCrossRef
24.
Zurück zum Zitat Thiefin G, Beaugerie L. Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectum. Joint Bone Spine 2005; 72(4): 286–94PubMedCrossRef Thiefin G, Beaugerie L. Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectum. Joint Bone Spine 2005; 72(4): 286–94PubMedCrossRef
25.
Zurück zum Zitat Wallace JL, McKnight W, Reuter BK, et al. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000; 119(3): 706–14PubMedCrossRef Wallace JL, McKnight W, Reuter BK, et al. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000; 119(3): 706–14PubMedCrossRef
26.
Zurück zum Zitat Wallace JL. Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol 2001; 15(5): 691–703PubMedCrossRef Wallace JL. Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol 2001; 15(5): 691–703PubMedCrossRef
27.
Zurück zum Zitat Rodriguez-Tellez M, Arguelles F, Herrerias Jr JM, et al. Antiinflammatory agents less dangerous for gastrointestinal tract. Curr Pharm Des 2001; 7(10): 951–76PubMedCrossRef Rodriguez-Tellez M, Arguelles F, Herrerias Jr JM, et al. Antiinflammatory agents less dangerous for gastrointestinal tract. Curr Pharm Des 2001; 7(10): 951–76PubMedCrossRef
28.
Zurück zum Zitat Whittle BJ. Gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Fundam Clin Pharmacol 2003; 17(3): 301–13PubMedCrossRef Whittle BJ. Gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Fundam Clin Pharmacol 2003; 17(3): 301–13PubMedCrossRef
29.
Zurück zum Zitat Jimenez MD, Martin MJ, Alarcon de la Lastra C, et al. Role of L-arginine in ibuprofen-induced oxidative stress and neutrophil infiltration in gastric mucosa. Free Radic Res 2004; 38(9): 903–11PubMedCrossRef Jimenez MD, Martin MJ, Alarcon de la Lastra C, et al. Role of L-arginine in ibuprofen-induced oxidative stress and neutrophil infiltration in gastric mucosa. Free Radic Res 2004; 38(9): 903–11PubMedCrossRef
30.
Zurück zum Zitat Pai R, Szabo IL, Giap AQ, et al. Nonsteroidal anti-inflammatory drugs inhibit re-epithelialization of wounded gastric monolayers by interfering with actin, Src, FAK, and tensin signaling. Life Sci 2001; 69(25–26): 3055–71PubMedCrossRef Pai R, Szabo IL, Giap AQ, et al. Nonsteroidal anti-inflammatory drugs inhibit re-epithelialization of wounded gastric monolayers by interfering with actin, Src, FAK, and tensin signaling. Life Sci 2001; 69(25–26): 3055–71PubMedCrossRef
31.
Zurück zum Zitat Okabe S, Amagase K. An overview of acetic acid ulcer models: the history and state of the art of peptic ulcer research. Biol Pharm Bull 2005; 28(8): 1321–41PubMedCrossRef Okabe S, Amagase K. An overview of acetic acid ulcer models: the history and state of the art of peptic ulcer research. Biol Pharm Bull 2005; 28(8): 1321–41PubMedCrossRef
32.
Zurück zum Zitat Tarnawski AS. Cellular and molecular mechanisms of gastrointestinal ulcer healing. Dig Dis Sci 2005; 50Suppl. 1: S24–33PubMedCrossRef Tarnawski AS. Cellular and molecular mechanisms of gastrointestinal ulcer healing. Dig Dis Sci 2005; 50Suppl. 1: S24–33PubMedCrossRef
33.
Zurück zum Zitat Mizuno H, Sakamoto C, Matsuda K, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997; 112(2): 387–97PubMedCrossRef Mizuno H, Sakamoto C, Matsuda K, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997; 112(2): 387–97PubMedCrossRef
34.
Zurück zum Zitat Ma L, del Soldato P, Wallace JL. Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: shifting the angiogenic balance. Proc Natl Acad Sci U S A 2002; 99(20): 13243–7PubMedCrossRef Ma L, del Soldato P, Wallace JL. Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: shifting the angiogenic balance. Proc Natl Acad Sci U S A 2002; 99(20): 13243–7PubMedCrossRef
35.
Zurück zum Zitat Sanchez-Fidalgo S, Martin-Lacave I, Illanes M, et al. Angiogenesis, cell proliferation and apoptosis in gastric ulcer healing: effect of a selective cox-2 inhibitor. Eur J Pharmacol 2004; 505(1–3): 187–94PubMedCrossRef Sanchez-Fidalgo S, Martin-Lacave I, Illanes M, et al. Angiogenesis, cell proliferation and apoptosis in gastric ulcer healing: effect of a selective cox-2 inhibitor. Eur J Pharmacol 2004; 505(1–3): 187–94PubMedCrossRef
36.
Zurück zum Zitat Chan FK, Sung JJ. Role of acid suppressants in prophylaxis of NSAID damage. Best Pract Res Clin Gastroenterol 2001; 15(3): 433–45PubMedCrossRef Chan FK, Sung JJ. Role of acid suppressants in prophylaxis of NSAID damage. Best Pract Res Clin Gastroenterol 2001; 15(3): 433–45PubMedCrossRef
37.
Zurück zum Zitat Elliott SL, Ferris RJ, Giraud AS, et al. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exp Pharmacol Physiol 1996; 23(5): 432–4PubMedCrossRef Elliott SL, Ferris RJ, Giraud AS, et al. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exp Pharmacol Physiol 1996; 23(5): 432–4PubMedCrossRef
38.
Zurück zum Zitat Green Jr FW, Kaplan MM, Curtis LE, et al. Effect of acid and pepsin on blood coagulation and platelet aggregation: a possible contributor to prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 1978; 74(1): 38–43PubMed Green Jr FW, Kaplan MM, Curtis LE, et al. Effect of acid and pepsin on blood coagulation and platelet aggregation: a possible contributor to prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 1978; 74(1): 38–43PubMed
39.
Zurück zum Zitat Levine RA, Schwartzel EH. Effect of indomethacin on basal and histamine stimulated human gastric acid secretion. Gut 1984; 25(7): 718–22PubMedCrossRef Levine RA, Schwartzel EH. Effect of indomethacin on basal and histamine stimulated human gastric acid secretion. Gut 1984; 25(7): 718–22PubMedCrossRef
40.
Zurück zum Zitat Rodriguez-Stanley S, Redinger N, Miner PB. Effect of naproxen on gastric acid secretion and gastric pH. Aliment Pharmacol Ther 2006; 23: 1719–24PubMedCrossRef Rodriguez-Stanley S, Redinger N, Miner PB. Effect of naproxen on gastric acid secretion and gastric pH. Aliment Pharmacol Ther 2006; 23: 1719–24PubMedCrossRef
41.
Zurück zum Zitat Thjodliefsson B. Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors. Drug Aging 2002; 19(12): 911–27CrossRef Thjodliefsson B. Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors. Drug Aging 2002; 19(12): 911–27CrossRef
42.
Zurück zum Zitat Bazzoli F, Palli D, Zagari RM. The Loiano-Monghidoro population-based study of Helicobacter pylori infection: prevalence by [13]C-urea breath test and associated test. Aliment Pharmacol Ther 2001; 15: 1001–7PubMedCrossRef Bazzoli F, Palli D, Zagari RM. The Loiano-Monghidoro population-based study of Helicobacter pylori infection: prevalence by [13]C-urea breath test and associated test. Aliment Pharmacol Ther 2001; 15: 1001–7PubMedCrossRef
43.
Zurück zum Zitat Haruma K, Mihara M, Okamoto E, et al. Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus: evaluation of 24-h pH monitoring. Aliment Pharmacol Ther 1999; 13: 155–62PubMedCrossRef Haruma K, Mihara M, Okamoto E, et al. Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus: evaluation of 24-h pH monitoring. Aliment Pharmacol Ther 1999; 13: 155–62PubMedCrossRef
44.
Zurück zum Zitat Labenz J, Tillenburg B, Peltz U, et al. Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. Am J Gastroenterol 1997; 92: 576–81PubMed Labenz J, Tillenburg B, Peltz U, et al. Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. Am J Gastroenterol 1997; 92: 576–81PubMed
45.
Zurück zum Zitat Chan FK. Management of high-risk patients on non-steroidal anti-inflammatory drugs or aspirin. Drugs 2006; 66Suppl. 1: 23–8PubMed Chan FK. Management of high-risk patients on non-steroidal anti-inflammatory drugs or aspirin. Drugs 2006; 66Suppl. 1: 23–8PubMed
46.
Zurück zum Zitat Lanas A, Ferrandez A. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention. Chin J Dig Dis 2006; 7(3): 127–33PubMedCrossRef Lanas A, Ferrandez A. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention. Chin J Dig Dis 2006; 7(3): 127–33PubMedCrossRef
47.
Zurück zum Zitat Ji KY, Hu FL. Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases. World J Gastroenterol 2006; 12(24): 3789–92PubMed Ji KY, Hu FL. Interaction or relationship between Helicobacter pylori and non-steroidal anti-inflammatory drugs in upper gastrointestinal diseases. World J Gastroenterol 2006; 12(24): 3789–92PubMed
48.
Zurück zum Zitat Huang J-Q, Sridhar S, Hunt R. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic ulcer disease: a meta-analysis. Lancet 2002; 359: 14–22PubMedCrossRef Huang J-Q, Sridhar S, Hunt R. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic ulcer disease: a meta-analysis. Lancet 2002; 359: 14–22PubMedCrossRef
49.
Zurück zum Zitat Pilotto A, Franceschi M, Leandro G, et al. The effect of Helicobacter pylori infection on NSAID-related gastrointestinal damage in the elderly. Eur J Gastroenterol Hepatol 1997; 9(10): 951–6PubMedCrossRef Pilotto A, Franceschi M, Leandro G, et al. The effect of Helicobacter pylori infection on NSAID-related gastrointestinal damage in the elderly. Eur J Gastroenterol Hepatol 1997; 9(10): 951–6PubMedCrossRef
50.
Zurück zum Zitat Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov 2003; 2(2): 132–9PubMedCrossRef Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov 2003; 2(2): 132–9PubMedCrossRef
51.
Zurück zum Zitat Handa O, Yoshida N, Fujita N, et al. Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors. Inflamm Res 2006; 55(11): 476–80PubMedCrossRef Handa O, Yoshida N, Fujita N, et al. Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors. Inflamm Res 2006; 55(11): 476–80PubMedCrossRef
52.
Zurück zum Zitat Lapenna D, de Gioia S, Ciofani G, et al. Antioxidant properties of omeprazole. FEBS Lett 1996; 382(1–2): 189–92PubMedCrossRef Lapenna D, de Gioia S, Ciofani G, et al. Antioxidant properties of omeprazole. FEBS Lett 1996; 382(1–2): 189–92PubMedCrossRef
53.
Zurück zum Zitat Agastya G, West BC, Callahan JM. Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro. Immunopharmacol Immunotoxicol 2000; 22(2): 357–72PubMedCrossRef Agastya G, West BC, Callahan JM. Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro. Immunopharmacol Immunotoxicol 2000; 22(2): 357–72PubMedCrossRef
54.
Zurück zum Zitat Suzuki M, Mori M, Miura S, et al. Omeprazole attenuates oxygen-derived free radical production from human neutrophils. Free Radic Biol Med 1996; 21(5): 727–31PubMedCrossRef Suzuki M, Mori M, Miura S, et al. Omeprazole attenuates oxygen-derived free radical production from human neutrophils. Free Radic Biol Med 1996; 21(5): 727–31PubMedCrossRef
55.
Zurück zum Zitat Wandall JH. Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut 1992; 33(5): 617–21PubMedCrossRef Wandall JH. Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut 1992; 33(5): 617–21PubMedCrossRef
56.
Zurück zum Zitat Becker JC, Grosser N, Waltke C, et al. Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells. Biochem Biophys Res Commun 2006; 345(3): 1014–21PubMedCrossRef Becker JC, Grosser N, Waltke C, et al. Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells. Biochem Biophys Res Commun 2006; 345(3): 1014–21PubMedCrossRef
57.
Zurück zum Zitat Fornai M, Natale G, Colucci R, et al. Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage. Naunyn Schmiedebergs Arch Pharmacol 2005; 372(1): 79–87PubMedCrossRef Fornai M, Natale G, Colucci R, et al. Mechanisms of protection by pantoprazole against NSAID-induced gastric mucosal damage. Naunyn Schmiedebergs Arch Pharmacol 2005; 372(1): 79–87PubMedCrossRef
58.
Zurück zum Zitat Biswas K, Bandyopadhyay U, Chattopadhyay I, et al. A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J Biol Chem 2003; 278(13): 10993–1001PubMedCrossRef Biswas K, Bandyopadhyay U, Chattopadhyay I, et al. A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J Biol Chem 2003; 278(13): 10993–1001PubMedCrossRef
59.
Zurück zum Zitat Koch TR, Petro A, Darrabie M, et al. Effects of esomeprazole magnesium on nonsteroidal anti-inflammatory drug gastropathy. Dig Dis Sci 2005; 50(1): 86–93PubMedCrossRef Koch TR, Petro A, Darrabie M, et al. Effects of esomeprazole magnesium on nonsteroidal anti-inflammatory drug gastropathy. Dig Dis Sci 2005; 50(1): 86–93PubMedCrossRef
60.
Zurück zum Zitat Szabo I, Tarnawski AS. Apoptosis in the gastric mucosa: molecular mechanisms, basic and clinical implications. J Physiol Pharmacol 2000; 51(1): 3–15PubMed Szabo I, Tarnawski AS. Apoptosis in the gastric mucosa: molecular mechanisms, basic and clinical implications. J Physiol Pharmacol 2000; 51(1): 3–15PubMed
61.
Zurück zum Zitat Villegas I, Martin MJ, La Casa C, et al. Effects of oxicam inhibitors of cyclooxygenase on oxidative stress generation in rat gastric mucosa: a comparative study. Free Radic Res 2002; 36(7): 769–77PubMedCrossRef Villegas I, Martin MJ, La Casa C, et al. Effects of oxicam inhibitors of cyclooxygenase on oxidative stress generation in rat gastric mucosa: a comparative study. Free Radic Res 2002; 36(7): 769–77PubMedCrossRef
62.
Zurück zum Zitat Savoye G, Miralles-Barrachina O, Dechelotte P, et al. Low levels of gastric mucosal glutathione during upper gastric bleeding associated with the use of nonsteroidal anti-inflammatory drugs. Eur J Gastroenterol Hepatol 2001; 13(11): 1309–13PubMedCrossRef Savoye G, Miralles-Barrachina O, Dechelotte P, et al. Low levels of gastric mucosal glutathione during upper gastric bleeding associated with the use of nonsteroidal anti-inflammatory drugs. Eur J Gastroenterol Hepatol 2001; 13(11): 1309–13PubMedCrossRef
63.
Zurück zum Zitat Verri M, Natale G, Boschi F, et al. Effects of esomeprazole sodium on glutathione levels in the gastric mucosa of rats treated with indomethacin [abstract]. Gastroenterology 2006; 130Suppl. 2: A270 Verri M, Natale G, Boschi F, et al. Effects of esomeprazole sodium on glutathione levels in the gastric mucosa of rats treated with indomethacin [abstract]. Gastroenterology 2006; 130Suppl. 2: A270
64.
Zurück zum Zitat Schmassmann A, Tarnawski A, Peskar BM, et al. Influence of acid and angiogenesis on kinetics of gastric ulcer healing in rats: interaction with indomethacin. Am J Physiol 1995; 268 (2 Pt 1): G276–85PubMed Schmassmann A, Tarnawski A, Peskar BM, et al. Influence of acid and angiogenesis on kinetics of gastric ulcer healing in rats: interaction with indomethacin. Am J Physiol 1995; 268 (2 Pt 1): G276–85PubMed
65.
Zurück zum Zitat Koh TJ, Chen D. Gastrin as a growth factor in the gastrointestinal tract. Regul Pept 2000; 93(1–3): 37–44PubMedCrossRef Koh TJ, Chen D. Gastrin as a growth factor in the gastrointestinal tract. Regul Pept 2000; 93(1–3): 37–44PubMedCrossRef
66.
Zurück zum Zitat Ito M, Segami T, Inaguma K, et al. Cimetidine and omeprazole accelerate gastric ulcer healing by an increase in gastrin secretion. Eur J Pharmacol 1994; 263(3): 253–9PubMedCrossRef Ito M, Segami T, Inaguma K, et al. Cimetidine and omeprazole accelerate gastric ulcer healing by an increase in gastrin secretion. Eur J Pharmacol 1994; 263(3): 253–9PubMedCrossRef
67.
Zurück zum Zitat Schmassmann A, Reubi JC. Cholecystokinin-B/gastrin receptors enhance wound healing in the rat gastric mucosa. J Clin Invest 2000; 106(8): 1021–9PubMedCrossRef Schmassmann A, Reubi JC. Cholecystokinin-B/gastrin receptors enhance wound healing in the rat gastric mucosa. J Clin Invest 2000; 106(8): 1021–9PubMedCrossRef
68.
Zurück zum Zitat Hawkey CJ, Talley NJ, Scheiman JM, et al. Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies. Arthritis Res Ther 2007; 9(1): R17–26PubMedCrossRef Hawkey CJ, Talley NJ, Scheiman JM, et al. Maintenance treatment with esomeprazole following initial relief of non-steroidal anti-inflammatory drug-associated upper gastrointestinal symptoms: the NASA2 and SPACE2 studies. Arthritis Res Ther 2007; 9(1): R17–26PubMedCrossRef
69.
Zurück zum Zitat Goldstein JL, Johanson JF, Suchower LJ, et al. Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial. Am J Gastroenterol 2005; 100(12): 2650–7PubMedCrossRef Goldstein JL, Johanson JF, Suchower LJ, et al. Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial. Am J Gastroenterol 2005; 100(12): 2650–7PubMedCrossRef
70.
Zurück zum Zitat Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352(3): 238–44PubMedCrossRef Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352(3): 238–44PubMedCrossRef
71.
Zurück zum Zitat Chan FK, Wong VW, Suen BY. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007; 369: 1621–6PubMedCrossRef Chan FK, Wong VW, Suen BY. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007; 369: 1621–6PubMedCrossRef
72.
Zurück zum Zitat Lai KC, Chu KM, Hui WM, et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol 2006; 4(7): 860–5PubMedCrossRef Lai KC, Chu KM, Hui WM, et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol 2006; 4(7): 860–5PubMedCrossRef
73.
Zurück zum Zitat Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006; 101(4): 701–10PubMedCrossRef Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006; 101(4): 701–10PubMedCrossRef
74.
Zurück zum Zitat Cryer B. A COX-2-specific inhibitor plus a proton-pump inhibitor: is this a reasonable approach to reduction in NSAIDs’ GI toxicity?. Am J Gastroenterol 2006; 101(4): 711–3PubMedCrossRef Cryer B. A COX-2-specific inhibitor plus a proton-pump inhibitor: is this a reasonable approach to reduction in NSAIDs’ GI toxicity?. Am J Gastroenterol 2006; 101(4): 711–3PubMedCrossRef
75.
Zurück zum Zitat Goldstein JL, Miner Jr PB, Schlesinger PK, et al. Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther 2006; 23(8): 1189–96PubMedCrossRef Goldstein JL, Miner Jr PB, Schlesinger PK, et al. Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther 2006; 23(8): 1189–96PubMedCrossRef
76.
Zurück zum Zitat Miner Jr P, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98(12): 2616–20PubMedCrossRef Miner Jr P, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98(12): 2616–20PubMedCrossRef
77.
Zurück zum Zitat Rohss K, Lind T, Wilder-Smith C. Esomeprazole 40mg provides more effective intragastric acid control than lansoprazole 30mg, omeprazole 20mg, pantoprazole 40mg and rabeprazole 20mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol 2004; 60(8): 531–9PubMedCrossRef Rohss K, Lind T, Wilder-Smith C. Esomeprazole 40mg provides more effective intragastric acid control than lansoprazole 30mg, omeprazole 20mg, pantoprazole 40mg and rabeprazole 20mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol 2004; 60(8): 531–9PubMedCrossRef
78.
Zurück zum Zitat Edwards SJ, Lind T, Lundell L. Proton pump inhibitors (PPIs) for the healing of reflux oesophagitis: a comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther 2006; 24(5): 743–50PubMedCrossRef Edwards SJ, Lind T, Lundell L. Proton pump inhibitors (PPIs) for the healing of reflux oesophagitis: a comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther 2006; 24(5): 743–50PubMedCrossRef
79.
Zurück zum Zitat Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000; 14(10): 1249–58PubMedCrossRef Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000; 14(10): 1249–58PubMedCrossRef
80.
Zurück zum Zitat Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Esomeprazole Study Investigators. Am J Gastroenterol 2001; 96(3): 656–65PubMedCrossRef Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Esomeprazole Study Investigators. Am J Gastroenterol 2001; 96(3): 656–65PubMedCrossRef
81.
Zurück zum Zitat Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is an effective therapy for maintaining healed erosive esophagitis and for controlling gastro-esophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001; 96(1): 27–34PubMedCrossRef Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is an effective therapy for maintaining healed erosive esophagitis and for controlling gastro-esophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001; 96(1): 27–34PubMedCrossRef
82.
Zurück zum Zitat Vakil NB, Shaker R, Johnson DA, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15(7): 927–35PubMedCrossRef Vakil NB, Shaker R, Johnson DA, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15(7): 927–35PubMedCrossRef
83.
Zurück zum Zitat Blume H, Donath F, Warnke A, et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 2006; 29(9): 769–84PubMedCrossRef Blume H, Donath F, Warnke A, et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 2006; 29(9): 769–84PubMedCrossRef
84.
Zurück zum Zitat Pilotto A, Franceschi M, Leandro G, et al. NSAID and aspirin use by the elderly in general practice: effect on gastrointestinal symptoms and therapies. Geriatric Gastroenterology Study Group. Drugs Aging 2003; 20(9): 701–10PubMedCrossRef Pilotto A, Franceschi M, Leandro G, et al. NSAID and aspirin use by the elderly in general practice: effect on gastrointestinal symptoms and therapies. Geriatric Gastroenterology Study Group. Drugs Aging 2003; 20(9): 701–10PubMedCrossRef
85.
Zurück zum Zitat Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs 2003; 63(24): 2739–54PubMedCrossRef Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs 2003; 63(24): 2739–54PubMedCrossRef
86.
Zurück zum Zitat Andersson T, Hassan-lin M, Hasselgreen G, et al. Drug interaction studies with esomeprazole, the (s)-isomer of omeprazole. Clin Pharmacokinet 2001; 40: 523–37PubMedCrossRef Andersson T, Hassan-lin M, Hasselgreen G, et al. Drug interaction studies with esomeprazole, the (s)-isomer of omeprazole. Clin Pharmacokinet 2001; 40: 523–37PubMedCrossRef
87.
Zurück zum Zitat Ishizaki T, Horai Y. Cytochrome P450 and the metabolism of proton pump inhibitors: emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13Suppl. 3: 27–36PubMedCrossRef Ishizaki T, Horai Y. Cytochrome P450 and the metabolism of proton pump inhibitors: emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13Suppl. 3: 27–36PubMedCrossRef
88.
Zurück zum Zitat Klotz U. Pharmacokinetic considerations in the eradication of Helicobacterpylori. Clin Pharmacokinet 2000; 38(3): 243–70PubMedCrossRef Klotz U. Pharmacokinetic considerations in the eradication of Helicobacterpylori. Clin Pharmacokinet 2000; 38(3): 243–70PubMedCrossRef
89.
Zurück zum Zitat Humphries TJ, Merritt GJ. Drug interactions with agents used to treat acid-related disease. Aliment Pharmacol Ther 1999; 13Suppl. 3: 18–26PubMedCrossRef Humphries TJ, Merritt GJ. Drug interactions with agents used to treat acid-related disease. Aliment Pharmacol Ther 1999; 13Suppl. 3: 18–26PubMedCrossRef
90.
Zurück zum Zitat Horai Y, Kimura M, Furuie H, et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment Pharmacol Ther 2001; 15: 793–803PubMedCrossRef Horai Y, Kimura M, Furuie H, et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment Pharmacol Ther 2001; 15: 793–803PubMedCrossRef
91.
Zurück zum Zitat Miura M, Inoue K, Kagaya H, et al. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. Biopharm Drug Dispos 2007; 28(4): 167–75PubMedCrossRef Miura M, Inoue K, Kagaya H, et al. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. Biopharm Drug Dispos 2007; 28(4): 167–75PubMedCrossRef
Metadaten
Titel
Clinical Efficacy of Esomeprazole in the Prevention and Healing of Gastrointestinal Toxicity Associated with NSAIDs in Elderly Patients
verfasst von
Dr Corrado Blandizzi
Marco Tuccori
Rocchina Colucci
Giovanni Gori
Matteo Fornai
Luca Antonioli
Narcisa Ghisu
Mario Del Tacca
Publikationsdatum
01.03.2008
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 3/2008
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.2165/00002512-200825030-00003

Weitere Artikel der Ausgabe 3/2008

Drugs & Aging 3/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.